Advertisement

Topics

Latest "Xoma Novartis Partner Beta MAbs Related" News Stories

13:35 EDT 26th April 2018 | BioPortfolio

Here are the most relevant search results for "Xoma Novartis Partner Beta MAbs Related" found in our extensive news archives from over 250 global news sources.

More Information about Xoma Novartis Partner Beta MAbs Related on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Xoma Novartis Partner Beta MAbs Related for you to read. Along with our medical data and news we also list Xoma Novartis Partner Beta MAbs Related Clinical Trials, which are updated daily. BioPortfolio also has a large database of Xoma Novartis Partner Beta MAbs Related Companies for you to search.

Showing "Xoma Novartis Partner Beta MAbs Related" News Articles 1–25 of 11,000+

Thursday 26th April 2018

SNOMED International Announces Brazil as its 33rd Member

London, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- Brazil's Ministry of Health and SNOMED International announce that as of April 1, 2018, Brazil has joined the organization as SNOMED International's thirty-third Member. With SNOMED CT already used in various parts of the country, Brazil joined SNOMED International to support nationwide health system transformation as a fo...


Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer

The National Cancer Institute, Laboratory of Molecular Biology seeks parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers. The antibody was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth in vitro Mesothelin is a cell surface protein t...

Diabetes, Obesity, and Other Insulin-Related Diseases

This technology claims methods for treating diseases or conditions associated with insulin resistance using the small molecule epoxy-guaiane derivative englerin A and related compounds. The compounds are claimed separately in a related NIH technology. The inventors have shown that englerin A, a compound originally isolated from the Phyllanthus plant and previously identified as an anti-cancer agen...


Topical Antibiotic for Faster Wound Healing

Currently available topical antibiotic formulations effectively eliminate bacteria at a wound site. Eliminating bacteria in the wound also eliminates the molecular signals present in bacterial DNA that stimulate the immune system's wound healing processes. Without these signals, the rate of wound healing is diminished.   The present technology provides a means of improving the activity of topic...

UOK 268 Cell Line for Hereditary Leiomyomatosis and Renal Cell Carcinoma

HLRCC is an extremely aggressive cancer syndrome with no effective treatment regimen and currently no cure.  The progress of identifying HLRCC treatments and cures has likely been hindered due to the lack of an HLRCC model for studying the cancer syndrome and for screening therapeutic drug candidates. This technology describes the UOK 268 cell line, a spontaneously immortalized renal tumor cell ...

High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research

The National Cancer Institute Laboratory of Molecular Biology seeks parties for collaborative research to co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.  There is great interest and value in developing more sensitive and efficient agents for earlier detection of hepatocellular cancer (HCC).  Glypican-3 (GPC3) is a cell surface heparin sulfate...

Improved Personalized Cancer Immunotherapy

Scientists at NIH have identified a process to select highly tumor-reactive T cells from a patient tumor sample based on the expression of four specific T cell surface markers: programmed cell death protein 1 (PD-1; CD279), 4-1BB (CD137), T cell lg-and mucin-domain-containing molecule-3 (TIM-3), and/or lymphocyte activation gene 3 (LAG-3). After this enriched population of tumor fighting T cells, ...

Sterculic Acid Treatment for Choroidal Neovascularization

Sterculic acid is a naturally occurring cyclopropene acid present in kapok seed oil, cottonseed oil, and in the seeds of the Sterculia foetida tree.  Sterculic acid has been reported to be a non-specific inhibitor of stearoyl-Co desaturase (SCD), which has been implicated in several disease states, including cardiovascular disease, obesity, non-insulin-dependent diabetes mellitus, skin disease, h...

Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)

The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment.  Therapeutics targeting TRAIL and its receptors are not only effective ...

Anti-Viral Compounds that Inhibit HIV Activity

Several novel tropolone derivatives have been identified that inhibit HIV-1 RNase H function and have potential for anti-viral activity due to reduced cellular toxicity.  Inhibiting RNase H function is a potential treatment for many viral infections, since RNase H function is essential for viral replication for many pathogenic retroviruses such as HIV-1 and HIV-2.  Although many hydroxytropolone...

Selective Treatment of Cancer Cells, HIV and Other RNA Viruses

The National Cancer Institute seeks parties interested in collaborative research to co-develop therapeutic RNA switches. Targeted therapy in cancer or viral infections is a challenge because the disease state manifests itself mainly through differences in the cell interior, for example in a form of the presence of a certain RNA or protein in the cytoplasm. This technology, developed at the NCI Nan...

Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C

The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG)  Immunoepidemiology Branch is seeking statements of capability or interest from parties interested in collaborative research to further co-develop a gene-based diagnostic for Hepatitis C virus (HepC, HCV). NCI Researchers have discovered Interferon-lambda 4 (IFNL4), a protein found through analysis of genomic ...

CrownBio Launches New Humanized Target Model for Immunotherapy

SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM(TM)) by ...

Aino Health AB (publ): Aino Health gains representation in the United Arab Emirates

    April 26, 2018 Aino Health gains representation in the United Arab Emirates Aino Health has entered into an exclusive partnership agreement with Emirates Artificial Intelligence Technologies LLC. Emirates A.I. as the company is known, will distribute Aino Health's solutions in the United Arab Emirates. "It is with great satisfaction that we enter into this par...

Gainline Capital Partners Makes Investment in Integrated Energy Services Corporation

iES Founder and CEO Brock Niggcommented, "We are excited to partner with Gainline as we execute on our strategic vision and enter the next Read more...

Compulink Showcases EHR Software for OB-GYN at ACOG 2018

All-in-One solution designed to streamline practice workflow and drive efficiency and profitability Compulink Business Systems, Inc., a recognized leader in specialty-specific EHR and Practice Management solutions will demonstrate the latest enhancements to its

How to eliminate gastric cancer-related death worldwide?

Anti-VEGF therapy — a role in obesity-related breast cancer

AmerisourceBergen Foundation Creates Opioid Resource Grant Program

Formalizes ongoing efforts made to fight opioid abuse Grants to be overseen by newly-formed External Advisory Committee comprised of experts on opioid abuse The AmerisourceBergen Foundation, a not-for-profit charitable organization focused on supporting health-related causes that enrich the global community, today announced the broadening of i...

MITA Seeks Third-Party Servicer Buy-In For Quality Standards Pending FDA Report

The Medical Imaging Technology Alliance has pulled together a consensus body of original equipment manufacturers, third-party servicers and others to...   

Boehringer Breathes Easy Over Spiriva Patent Expiry In US

The German group's pharma chief told Scrip that he does not expect to see any competition in the US in...    

VSee and CloudMinds Technology To Provide Cloud-based AI for Conversational Telemedicine Applications

VSee telemedicine platform, and CloudMinds advanced Cloud AI engines, partner for a healthcare solution to support efficient patient/doctor remote communication and learning CHICAGO (PRWEB) April 26, 2018 VSee and CloudMinds Technology today announced a partnership to overcome key challenges in next generation telemedicine application delivery. While the promise of telemedicine is great, obstacl...

10x Genomics Completes $50 Million Series D Financing and $75M Credit Facility

10x Genomics, a company focused on accelerating genomic discovery, today announced that it had raised $125 million in funding. The funding included a $50 million Series D financing. It was led by Meritech Capital Partners and included new investor Wells Fargo Strategic Capital along with current investors Paladin Capital, Fidelity and the SoftBank Group. T...

Innoviva Reports First Quarter 2018 Financial Results

Royalties earned rose 28% to $55.8 million compared with the first quarter of 2017. Net income attributable to Innoviva stockholders increased 76% from the first quarter of 2017 to $29.6 million, or $0.29 per basic share. Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the first quarte...

Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting

– Oral presentation to highlight preliminary results of ACE-083’s Phase 2 trial in patients with facioscapulohumeral muscular dystrophy – – Part 2 of the ongoing Phase 2 trial in patients with facioscapulohumeral muscular dystrophy has been initiated – Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the di...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks